Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 222.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $222.15 | 52 Week High | $333.65 | |||
| Open | $222.15 | 52 Week Low | $223.02 | |||
| Day High | $222.15 | P/E | 28.44 | |||
| Day Low | $222.15 | EPS | $7.81 | |||
| Volume | 1,108 | |||||
